Dr. George P. Vlasuk is a scientifically trained executive with nearly 40 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies.
George was previously President, CEO, and CSO of Navitor Pharmaceuticals, Inc., and currently serves as a board member and consultant. He also serves on the Boards of Nimbus Therapeutics and Riparian Pharmaceuticals as well as a consultant and scientific advisor to several biopharmaceutical companies. Before joining Navitor, George served as CEO of Sirtris, a GlaxoSmithKline Company. Prior to Sirtris, he was Vice President, Metabolic Disease and Hemophilia Research, at Wyeth Pharmaceuticals. Dr. Vlasuk also previously served as Chief Scientific Officer and Executive Vice President of Research and Development at Corvas International, prior to the merger of Corvas and Dendreon Corporation. Earlier in his career, George led a research team at Merck and Co., and was responsible for multiple discovery programs in the field of cardiovascular medicine. He is the author of more than 100 peer-reviewed scientific publications, book chapters, and reviews, and 38 issued U.S. and foreign patents.